ADMA Biologics Shareholders Offered Chance to Lead Securities Fraud Lawsuit
Investors who lost money in ADMA Biologics have the opportunity to lead a securities fraud class action lawsuit. The Law Offices of Frank R. Cruz is initiating the litigation, alleging undisclosed related party transactions and revenue inflation.
ADMA Biologics, Inc. (NASDAQ: ADMA) shareholders who experienced financial losses are being offered the chance to lead a securities fraud class action lawsuit. The Law Offices of Frank R. Cruz announced on July 9, 2026, that they are spearheading legal action concerning alleged fraudulent practices within the company.
The complaint, filed for the period between August 9, 2024, and March 25, 2026, asserts that ADMA Biologics' management failed to disclose critical information to investors. These alleged omissions include undisclosed related-party transactions, the use of "channel stuffing" to artificially inflate revenue figures, and inadequate internal controls. The lawsuit contends that these actions rendered the company's positive statements about its business operations and prospects materially misleading.
The Law Offices of Frank R. Cruz is urging any investor who incurred losses in ADMA Biologics stock during the specified timeframe to come forward before the August 10, 2026, deadline. This date serves as the Lead Plaintiff deadline, a crucial point for individuals seeking to participate and potentially be appointed as the lead plaintiff in the class action.
The law firm is continuing its investigation and invites investors seeking more information about the lawsuit or their rights to make contact. Details provided include email, phone, and a website for further inquiries. The objective of the legal action is to hold management accountable and pursue compensation for affected shareholders.